Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Therapeutic
- Disease
- Central Nervous System
- Delivery
- Drug Discovery
- Medical
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 240440
License Grant
The Taiwan Licensee obtained from the Taiwan Licensor the exclusive global rights to PDC-1421, an API, and its surrounding proprietary information to develop, manufacture, distribute and sell pharmaceutical products for potential use in major depressive disorders.
License Property
PDC-1421, an API for possible use in major depressive disorder with Montgomery-Asberg Depression Rating Scale.
Field of Use
With PDC-1421 as the API, the Licensee is developing two new drug candidates, BLI-1005 to treat MDD and BLI-1008 for ADHD.
Major depressive disorder (MDD), also known simply as depression, is a mental disorder characterized by at least two weeks of low mood that is present across most situations. It is often accompanied by low self-esteem, loss of interest in normally enjoyable activities, low energy, and pain without a clear cause.
Attention deficit hyperactivity disorder (ADHD) is a mental health disorder that can cause above-normal levels of hyperactive and impulsive behaviors. People with ADHD may also have trouble focusing their attention on a single task or sitting still for long periods of time. Both adults and children can have ADHD.
IPSCIO Record ID: 315667
License Grant
The Swiss Licensee obtained a worldwide, sub-licensable license from the Licensor covering four different compounds, which included Mazindol (the “Licensed Compoundsâ€). Under the Second Amendment it was agreed to include sales realized upon the commercialization of products developed on the basis of the Licensed Compounds during the terms of their respective patents. The Licensee’s majority shareholders are also majority shareholders in the Licensor and as such are considered to be related parties.
License Property
Licensed Compound, Mazindol, is an active molecule in a proprietary controlled release formulation. The controlled-release formulations are being designed to optimize their pharmacokinetic and pharmacodynamic properties with a rapid onset of action and prolonged controlled therapeutic effect, allowing for a daily oral dose that effectively provides consistent and long acting symptom control and designed to uniquely meet the needs of patients.
Licensor is primarily focusing on the repurposing of safe and (cost-)effective compounds to treat Attention Deficit/HyperActivity Disorder (ADHD), sleep disorders and cognitive impairment.
Field of Use
Licensee will utilize Mazindol, an active substance, to cover a range of areas including the therapeutic use of mazindol for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and combination therapies containing mazindol (add-ons with iron or stimulants) as well as sleep disorders such as narcolepsy or idiopathic hypersomnia. Attention Deficit Hyperactivity Disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness.
Licensee is an innovative biotechnology company engaged in the discovery and development of life-improving drug therapies to treat rare and complex central nervous system, or CNS, disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder, or ADHD. CNS disorders are a diverse group of conditions that include neurological, psychiatric, and substance use disorders.
IPSCIO Record ID: 287024
License Grant
Licensor has the right to receive a royalty generated by KP415, KP484 or KP879, and any product candidates arising therefrom, including royalty payments on any license of KP415, KP484 or KP879, the sale of KP415, KP484 or KP879 to a third party, the commercialization of KP415, KP484 or KP879.
License Property
The products for the treatment of ADHD include KP415 and KP484, and the Companys preclinical product candidate for the treatment of SUD includes KP879.
Field of Use
KP415 is Licensee’s prodrug product candidate being developed for the treatment of ADHD. KP415 consists of serdexmethylphenidate (SDX), Licensee’s prodrug of d-methylphenidate (d-MPH), co-formulated with immediate-release d-MPH. KP415 is designed to address unmet needs with the most prescribed methylphenidate ADHD treatments, including earlier onset of action and longer duration of therapy. In addition, the results from the Human Abuses Potential program for the SDX component of KP415 suggest that the prodrug may have lower abuse potential than relevant d-MPH comparators.
KP484 is Licensee’s co-lead clinical development candidate being developed for the treatment of ADHD in patients that respond best when a very long duration of therapy is required. Similar to KP415, KP484 consists of SDX, Licensee’s prodrug of d-MPH. Preclinical and clinical studies of KP484 have demonstrated that the prodrug may produce a longer duration release of d-MPH compared to the most prescribed methylphenidate products. KP484 has the potential to be the first new methylphenidate-based product being developed with the intent to address the specific needs of the adult ADHD population.
Attention deficit hyperactivity disorder (ADHD) is a mental disorder of the neurodevelopmental type. It is characterized by difficulty paying attention, excessive activity and acting without regards to consequences, which are otherwise not appropriate for a person's age.
KP879 is an extended-duration, agonist replacement therapy for the treatment of Stimulant Use Disorder, or SUD.
A substance use disorder (SUD), also known as a drug use disorder, is a medical condition in which the use of one or more substances leads to a clinically significant impairment or distress.
IPSCIO Record ID: 346433
License Grant
Israel Licensee was granted an exclusive license to intellectual property that can be used for research, development, marketing and manufacturing of products in the field of TMS treatment and may have the right to grant sublicenses in the original agreement by Israel Licensor, the technology transfer company of the University. Under the fifth addendum, Licensee received the right to examine an additional invention based upon the patent issued in connection with research in the field of rotational electrical fields owned by Licensor. Licensee has the right to include the aforementioned invention and the intellectual property accompanying it under the Licensor license agreement.
License Property
Invention and the intellectual property includes but not limited to TMS treatment including the field of rotational electrical fields.
Transcranial Magnetic Stimulation (TMS) uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The technology can either increase brain activity in neuronal networks which are hypoactive, or alternatively decrease brain activity in neuronal networks which are hyperactive. The proprietary electromagnetic coils, which is referred to as H-Coils, are designed to safely stimulate deep and broad brain regions.
Field of Use
Field of use is for the treatment of a wide range of additional psychiatric, neurological, and addiction disorders such as the treatment of major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and smoking addiction; including the field of rotational electrical fields.
MDD is a common and debilitating mental disorder characterized by physiological symptoms, such as sleep disturbance and changes in appetite, emotional symptoms, such as sadness, despair, emptiness, self-hate, and critique, and cognitive symptoms, such as difficulty concentrating, memory dysfunction, suicidal thinking, and faulty judgment of reality.
OCD is a common, chronic, and long-lasting disorder in which a person has uncontrollable, reoccurring thoughts (obsessions) and behaviors (compulsions) that he or she feels the urge to repeat over and over in a manner that can interfere with all aspects of life, such as work, school, and personal relationships.
Smoking is one of the leading causes of death in developed countries. The addiction to nicotine, similar to the addiction to drugs and alcohol, involves modulation of the brain reward system and causes uncontrollable desire to smoke. 480,000 U.S. adults die from smoking each year. Cigarette smoking has been found to harm nearly every organ system in the body and is the leading cause of preventable death in the U.S. and of disease burden worldwide.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
